GlaxoSmithKline's total assets for Q2 2026 were £61.74B, a decrease of -1.80% from the previous quarter. CH:GS71 total liabilities were £44.56B for the fiscal quarter, a -1.95% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.